High prevalence of resistance to first-line drugs and multidrug resistance in patients with tuberculosis and type 2 diabetes mellitus at a referral hospital in Peru
Open Access
- 20 August 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0337152
Abstract
Introduction: The coexistence of tuberculosis (TB) and type 2 diabetes mellitus (T2DM) poses an emerging public health challenge, especially in high-TB-burden settings such as Peru. This comorbidity has been associated to unfavorable clinical outcomes and a higher frequency of drug-resistant TB. Objective: To estimate the prevalence of resistance to first-line antituberculosis drugs and identify factors associated with multidrug resistance tuberculosis (MDR-TB) among patients with T2DM and pulmonary TB treated at a public hospital in Lima, Peru. Methods: A cross-sectional study was conducted using secondary data from 130 adults with T2DM and microbiologically confirmed pulmonary TB treated at a Peruvian hospital between 2015 and 2019. Drug susceptibility results were categorized as susceptible, monoresistant, polyresistant, or MDR-TB. Factors associated with MDR and resistance to at least one first-line drug were evaluated using Poisson regression models with robust variance. Results: The prevalence of resistance to at least one first-line drug was 34.6%, and the prevalence of MDR-TB was 21.5%. The most frequent resistances were to isoniazid (28.4%) and rifampicin (26.2%). In the multivariable analysis, age 40–49 years (aPR = 2.99; 95% CI: 1.00–8.97) and age 70–85 years (aPR = 4.13; 95% CI: 1.16–14.7) and were independently associated with MDR-TB. Furthermore, a diabetes duration of at least 5 years was associated with resistance to at least one drug (aPR ≈ 2.1). Conclusion: A high prevalence of drug resistance, including MDR-TB was observed among patients with T2DM and pulmonary TB. Older age and longer duration of diabetes were associated with bacterial resistance in the adjusted analysis. These findings underscore the importance of considering diabetes-related clinical characteristics when evaluating drug resistance patterns in patients with tuberculosis.Keywords
This publication has 31 references indexed in Scilit:
- Tuberculosis in South Asia: A regional analysis of burden, progress, and future projections using the global burden of disease (1990–2021)Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2024
- Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From ChinaClinical Infectious Diseases, 2024
- Daily monitoring of diabetic treatment amongst TB-DM patients under NTEP: Does it improve the treatment outcomes?Clinical Epidemiology and Global Health, 2022
- Incidence and prevalence of pulmonary tuberculosis among patients with type 2 diabetes mellitus: a systematic review and meta-analysisAnnals of Medicine, 2022
- The escalating tuberculosis crisis in central and South American prisonsThe Lancet, 2021
- A novel risk factor for predicting anti-tuberculosis drug resistance in patients with tuberculosis complicated with type 2 diabetes mellitusInternational Journal of Infectious Diseases, 2020
- Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis TreatmentClinical Infectious Diseases, 2017
- The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomesTuberculosis, 2017
- Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in PeruInternational Journal of Infectious Diseases, 2013
- The Dynamics of Tuberculosis in Response to 10 Years of Intensive Control Effort in PeruThe Journal of Infectious Diseases, 2001